Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression.

@article{Yoo2007ClevudineIH,
  title={Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression.},
  author={Byung Chul Yoo and Ju Hyun Kim and Tae Hoon Kim and Kwang Cheol Koh and S. Um and Young Soo Kim and Kwan Sik Lee and Byung Hoon Han and Chae yoon Chon and Jung-Yeol Han and Soo Hyung Ryu and Haak Cheoul Kim and Kwan Soo Byun and Seong Gyu Hwang and Byung-Ik Kim and Mong Cho and Kwon Cheol Yoo and Hanbyeol Lee and Jae Seok Hwang and Yun Kim and Young-Suk Lee and Sung Kyu Choi and Young Woo Lee and Jin-Mo Yang and Joong-Won Park and Meng Lee and Dae-Ghon Kim and Yung Khee Chung and Sang Min Cho and Jong Yeong Choi and Yeong-jin Kweon and Heon Young Lee and Sook-Hyang Jeong and Hee-Won Yoo and Hyo-suk Lee},
  journal={Hepatology},
  year={2007},
  volume={46 4},
  pages={
          1041-8
        }
}
UNLABELLED Clevudine is a pyrimidine analog with potent and sustained antiviral activity against HBV. In the present study, we evaluated the safety and efficacy of clevudine 30 mg daily for 24 weeks and assessed the durability of antiviral response for 24 weeks after cessation of dosing in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (e-CHB). We randomized a total of 86 patients (3:1) to receive clevudine 30 mg (n = 63) or placebo (n = 23) daily for 24 weeks. We followed patients… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 43 CITATIONS

Similar Papers

Loading similar papers…